期刊文献+

术前应用替罗非班对急性心肌梗死患者急诊经皮冠状动脉介入治疗疗效的分析 被引量:4

Analysis of Preoperative Use of Tirofiban in Percutaneous Coronary Intervention for Patients with Acute ST-segment Elevation Myocardial Infarction
下载PDF
导出
摘要 目的探讨在急性ST段抬高型心肌梗死(ST segment elevation myocardial infarction,STEMI)患者行急诊经皮冠状动脉介入治疗(percuteous coronary intervention,PCI)时,术前静脉注射替罗非班对术后冠脉血流及近期疗效的影响。方法 93例急性STEMI患者行急诊PCI治疗,随机分为术前静脉注射替罗非班(早期组,46例)和造影后静脉注射替罗非班(晚期组,47例)两组。分析两组患者术前基础临床情况、术前梗死相关血管前向血流情况、术后冠脉TIMI血流分级、校正的TIMI血流计数帧数(corrected TIMI frame count,CTFC)、射线照射时间及造影剂用量、左心室射血分数、术后3个月主要心血管事件(major adversecardiac events,MACE)。结果两组患者基础临床情况差异无统计学意义,早期组患者术前梗死相关动脉(infarction related arter-y,IRA)前向血流达到TIMI2~3级的比例高于晚期组(分别为30%和13%,P=0.038)。两组患者术后IRA前向血流达到TIMI3级的比例、心功能、近期MACE比较差异无统计学意义,但早期组患者射线照射时间、CTFC及造影剂用量均少于晚期组,两组比较差异有统计学意义(P<0.05)。结论急性STEMI行急诊PCI时,替罗非班注射液的不同应用时间对近期的临床预后虽然没有明显改善,但术前静脉应用可以提高IRA前向血流TIMI3级的比例,减少射线照射及手术时间。不同应用方法均不增加出血发生率,临床应用安全有效。 Objective To explore the effect of preoperative use of tirofiban on coronary flow and early effect on percutaneous coro- nary intervention(PCI) in patients with acute st - segment elevation myocardial infarction ( STEMI). Methods Totally 93 patients with STEMI were randomly divided into preoperative use of tirofiban (early group, n = 46) and post- coronary arteriongraphy use of tirofiban (late group, n = 47 ). Based clinical characteristics and blood flow of infarction related artery (IRA) data, TIMI blood flow grade after PCI,eorrectcd TIMI frame count(CTFC) , X -ray exposure time, amount of eonstrast agent, left ventrieular ejection fraction (LVEF) , major adverse cardiac events rates(MACE) within 3 months after PCI were analyzed. Results There was no statistical significance in the clinical data between the two groups. In early group, the rate of IRA achieved TIMI2 -3 before operation was higher than the late group (30% vs 13% , P = 0. 038). There was no statistical significance in the rate of IRA achieved TIMI3 after operation and heart function and early MACE between the two groups. X - ray exposure time and CTFC and amount of constrast agent were less than late group (P 〈 0.05). Conclusion Though different initiation of tiroflban in patients with acute STEMI treated by PCI can not improve early clinical outcome, high rate of IRA achieved TIMI3 and less X - ray exposure time and operation time were obtained. There was no increase in the incidence of bleeding. It was a safe and effective treatment.
出处 《医学研究杂志》 2012年第3期148-150,共3页 Journal of Medical Research
关键词 心肌梗死 经皮冠状动脉介入治疗 替罗非班 Myocardial infarction Percutaneous coronary intervention Tirofiban
  • 相关文献

参考文献4

  • 1Van't Hof AW ,Ten Berg J, Heestermans T, et al. Prehospital initiation of tirofiban in patients with ST - elevation myocardial infarction undergoing primary angioplasty ( On - TIME 2 ) : a multicentre, double - blind, randomized controlled trial [ J ]. Lancet,2008,372 ( 9638 ) : 537 - 546.
  • 2Rezkalla SH, Kloner RA. No - reflow phenomenon [ J ]. Circulation, 2002,105 (5) :656 - 662.
  • 3Lee DP, Herity NA, Hiatt BL, et al. Adjunctive platelet glycoprotein Ⅱ b/Ⅲa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes:results of the Tirofiban Given in the Emergency Room before Primary Angioplasty (TIGER - PA) pilot trial [ J]. Circulation ,2003,107 ( 11 ) : 1497 - 1501.
  • 4Petronlo AS, Rovai D,Musumeci G,et aL Effects of abciximab on microvascular integrity and left ventricular functional recovery in patients with acute infarction treated by primary coronary angioplasty [ J ]. Eur Heart J,2003,24(1) :67 -76.

同被引文献50

  • 1曹绪芬,卢清龙,韩立宪,袁琛,王钢,赵荣诚,王娟,程晓明.盐酸替罗非班在急性心肌梗死患者急诊冠状动脉介入治疗围术期的应用[J].中国介入心脏病学杂志,2006,14(3):176-178. 被引量:10
  • 2徐立,杨新春,王乐丰,葛永贵,王红石,李惟铭,倪祝华,刘宇,崔亮.提前应用替罗非班对急性ST段抬高心肌梗死患者急诊介入治疗疗效的影响[J].中华心血管病杂志,2006,34(11):983-986. 被引量:48
  • 3Lippi G,Montagnana M, Danese E, et al. G|ycoprotein 11 b/ Ill ainhibitors: an update on the mechanism of ac tion and use of functional testing methods to assess anti platelet efficacy [J]. Biomark Med,2011,5(1) :63-70.
  • 4Roe M T,Armstrong P W, Fox K A, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization[J]. N Engl J Med, 2012,367 : 1297-1309.
  • 5Cannon C P, Harrington R A, James S, et al. Compari- son of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO) :a randomized double-blind study[J]. Lancet, 2010,375:283-293.
  • 6Roggeri A, Gnavi R, Dalmasso M, et al. Resource consumption and healthcare costs of acute coronary syndrome: a retrospective observational administrative database analysis [J]. Crit Pathw Cardiol, 2013, 12 (4) 204-209.
  • 7L6pez-Cuenca AA, Tello-Montoliu A, Rolddn V, et al. Prognostic value of mean platelet volume in patients with non- ST-elevation acute coronary syndrome[J]. Angiology, 2012, 63 (4) : 241-244.
  • 8Dores H, Aguiar C, Ferreira J, et al. Compliance of pharmacological treatment for non-ST-elevation acute coronary syndromes with contemporary guidelines influence on outcomes[J]. Cardiovasc Diagn Ther,2014,4(1):13 20.
  • 9Paarup Dridi N, Johansson PI, Lonborg JT, et al. Tailored antiplatelet therapy to improve prognosis in patients exhibiting clopidogrel low-response prior to percutaneous coronary intervention for stable angina or non-ST elevationacute coronary syndrome[J]. Platelets,2015,26(6): 521-529.
  • 10Patel PD, Arora RR. Practical implications of ACC/AHA 2007 guidelines for the management of unstable angina/non- ST elevation myocardial infarction[J]. Am J Ther, 2010, 17 (1) :24-40.

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部